Olanzapine versus ziprasidone: Results of a 23-week double-blind study in patients with schizophrenia

Alan Breier, Paul H. Berg, Jogin H. Thakore, Dieter Naber, Wagner F. Gattaz, Patrizia Cavazzoni, Daniel J. Walker, Suraja M. Roychowdhury, John M. Kane

Research output: Contribution to journalArticle

115 Citations (Scopus)

Abstract

Objective: The efficacy and safety of olanzapine were compared with those of ziprasidone. Method: This was a multicenter randomized, double-blind, parallel-group, 28-week study of patients with schizophrenia. Patients were randomly assigned to treatment with 10-20 mg/day of olanzapine or 80-160 mg/day of ziprasidone. The primary efficacy measure was the Positive and Negative Syndrome Scale total score. Secondary efficacy and safety measures included Positive and Negative Syndrome Scale subscales as well as mood, quality of life, and extrapyramidal symptom scales. Safety was evaluated by recording treatment-emergent adverse events and measuring vital signs and weight. Results: The study was completed by significantly more olanzapine-treated patients (165 of 277, 59.6%) than ziprasidone-treated patients (115 of 271, 42.4%). At 28 weeks, the olanzapine-treated patients showed significantly more improvement than the ziprasidone-treated patients on the Positive and Negative Syndrome Scale overall scale and all subscales and on the Clinical Global Impression ratings of severity of illness and improvement. The responder rate was higher for olanzapine than for ziprasidone. Extrapyramidal symptoms were not significantly different between groups in change-to-endpoint analyses, but results favored olanzapine on baseline-to-maximum changes. Weight change was significantly greater with olanzapine (mean=3.06 kg, SD=6.87) than with ziprasidone (mean=-1.12 kg, SD=4.70). Fasting lipid profiles were significantly superior in the ziprasidone group; there was no significant difference in fasting glucose level. Conclusions: Olanzapine treatment resulted in significantly greater psychopathology improvement and higher response and completion rates than ziprasidone treatment, while ziprasidone was superior for weight change and lipid profile.

Original languageEnglish (US)
Pages (from-to)1879-1887
Number of pages9
JournalAmerican Journal of Psychiatry
Volume162
Issue number10
DOIs
StatePublished - Oct 2005

Fingerprint

olanzapine
Double-Blind Method
Schizophrenia
Safety
Weights and Measures
Fasting
Lipids
ziprasidone
Vital Signs
Therapeutics
Psychopathology

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

Olanzapine versus ziprasidone : Results of a 23-week double-blind study in patients with schizophrenia. / Breier, Alan; Berg, Paul H.; Thakore, Jogin H.; Naber, Dieter; Gattaz, Wagner F.; Cavazzoni, Patrizia; Walker, Daniel J.; Roychowdhury, Suraja M.; Kane, John M.

In: American Journal of Psychiatry, Vol. 162, No. 10, 10.2005, p. 1879-1887.

Research output: Contribution to journalArticle

Breier, A, Berg, PH, Thakore, JH, Naber, D, Gattaz, WF, Cavazzoni, P, Walker, DJ, Roychowdhury, SM & Kane, JM 2005, 'Olanzapine versus ziprasidone: Results of a 23-week double-blind study in patients with schizophrenia', American Journal of Psychiatry, vol. 162, no. 10, pp. 1879-1887. https://doi.org/10.1176/appi.ajp.162.10.1879
Breier, Alan ; Berg, Paul H. ; Thakore, Jogin H. ; Naber, Dieter ; Gattaz, Wagner F. ; Cavazzoni, Patrizia ; Walker, Daniel J. ; Roychowdhury, Suraja M. ; Kane, John M. / Olanzapine versus ziprasidone : Results of a 23-week double-blind study in patients with schizophrenia. In: American Journal of Psychiatry. 2005 ; Vol. 162, No. 10. pp. 1879-1887.
@article{fde844001af040fdae8ea60c9127516b,
title = "Olanzapine versus ziprasidone: Results of a 23-week double-blind study in patients with schizophrenia",
abstract = "Objective: The efficacy and safety of olanzapine were compared with those of ziprasidone. Method: This was a multicenter randomized, double-blind, parallel-group, 28-week study of patients with schizophrenia. Patients were randomly assigned to treatment with 10-20 mg/day of olanzapine or 80-160 mg/day of ziprasidone. The primary efficacy measure was the Positive and Negative Syndrome Scale total score. Secondary efficacy and safety measures included Positive and Negative Syndrome Scale subscales as well as mood, quality of life, and extrapyramidal symptom scales. Safety was evaluated by recording treatment-emergent adverse events and measuring vital signs and weight. Results: The study was completed by significantly more olanzapine-treated patients (165 of 277, 59.6{\%}) than ziprasidone-treated patients (115 of 271, 42.4{\%}). At 28 weeks, the olanzapine-treated patients showed significantly more improvement than the ziprasidone-treated patients on the Positive and Negative Syndrome Scale overall scale and all subscales and on the Clinical Global Impression ratings of severity of illness and improvement. The responder rate was higher for olanzapine than for ziprasidone. Extrapyramidal symptoms were not significantly different between groups in change-to-endpoint analyses, but results favored olanzapine on baseline-to-maximum changes. Weight change was significantly greater with olanzapine (mean=3.06 kg, SD=6.87) than with ziprasidone (mean=-1.12 kg, SD=4.70). Fasting lipid profiles were significantly superior in the ziprasidone group; there was no significant difference in fasting glucose level. Conclusions: Olanzapine treatment resulted in significantly greater psychopathology improvement and higher response and completion rates than ziprasidone treatment, while ziprasidone was superior for weight change and lipid profile.",
author = "Alan Breier and Berg, {Paul H.} and Thakore, {Jogin H.} and Dieter Naber and Gattaz, {Wagner F.} and Patrizia Cavazzoni and Walker, {Daniel J.} and Roychowdhury, {Suraja M.} and Kane, {John M.}",
year = "2005",
month = "10",
doi = "10.1176/appi.ajp.162.10.1879",
language = "English (US)",
volume = "162",
pages = "1879--1887",
journal = "American Journal of Psychiatry",
issn = "0002-953X",
publisher = "American Psychiatric Association",
number = "10",

}

TY - JOUR

T1 - Olanzapine versus ziprasidone

T2 - Results of a 23-week double-blind study in patients with schizophrenia

AU - Breier, Alan

AU - Berg, Paul H.

AU - Thakore, Jogin H.

AU - Naber, Dieter

AU - Gattaz, Wagner F.

AU - Cavazzoni, Patrizia

AU - Walker, Daniel J.

AU - Roychowdhury, Suraja M.

AU - Kane, John M.

PY - 2005/10

Y1 - 2005/10

N2 - Objective: The efficacy and safety of olanzapine were compared with those of ziprasidone. Method: This was a multicenter randomized, double-blind, parallel-group, 28-week study of patients with schizophrenia. Patients were randomly assigned to treatment with 10-20 mg/day of olanzapine or 80-160 mg/day of ziprasidone. The primary efficacy measure was the Positive and Negative Syndrome Scale total score. Secondary efficacy and safety measures included Positive and Negative Syndrome Scale subscales as well as mood, quality of life, and extrapyramidal symptom scales. Safety was evaluated by recording treatment-emergent adverse events and measuring vital signs and weight. Results: The study was completed by significantly more olanzapine-treated patients (165 of 277, 59.6%) than ziprasidone-treated patients (115 of 271, 42.4%). At 28 weeks, the olanzapine-treated patients showed significantly more improvement than the ziprasidone-treated patients on the Positive and Negative Syndrome Scale overall scale and all subscales and on the Clinical Global Impression ratings of severity of illness and improvement. The responder rate was higher for olanzapine than for ziprasidone. Extrapyramidal symptoms were not significantly different between groups in change-to-endpoint analyses, but results favored olanzapine on baseline-to-maximum changes. Weight change was significantly greater with olanzapine (mean=3.06 kg, SD=6.87) than with ziprasidone (mean=-1.12 kg, SD=4.70). Fasting lipid profiles were significantly superior in the ziprasidone group; there was no significant difference in fasting glucose level. Conclusions: Olanzapine treatment resulted in significantly greater psychopathology improvement and higher response and completion rates than ziprasidone treatment, while ziprasidone was superior for weight change and lipid profile.

AB - Objective: The efficacy and safety of olanzapine were compared with those of ziprasidone. Method: This was a multicenter randomized, double-blind, parallel-group, 28-week study of patients with schizophrenia. Patients were randomly assigned to treatment with 10-20 mg/day of olanzapine or 80-160 mg/day of ziprasidone. The primary efficacy measure was the Positive and Negative Syndrome Scale total score. Secondary efficacy and safety measures included Positive and Negative Syndrome Scale subscales as well as mood, quality of life, and extrapyramidal symptom scales. Safety was evaluated by recording treatment-emergent adverse events and measuring vital signs and weight. Results: The study was completed by significantly more olanzapine-treated patients (165 of 277, 59.6%) than ziprasidone-treated patients (115 of 271, 42.4%). At 28 weeks, the olanzapine-treated patients showed significantly more improvement than the ziprasidone-treated patients on the Positive and Negative Syndrome Scale overall scale and all subscales and on the Clinical Global Impression ratings of severity of illness and improvement. The responder rate was higher for olanzapine than for ziprasidone. Extrapyramidal symptoms were not significantly different between groups in change-to-endpoint analyses, but results favored olanzapine on baseline-to-maximum changes. Weight change was significantly greater with olanzapine (mean=3.06 kg, SD=6.87) than with ziprasidone (mean=-1.12 kg, SD=4.70). Fasting lipid profiles were significantly superior in the ziprasidone group; there was no significant difference in fasting glucose level. Conclusions: Olanzapine treatment resulted in significantly greater psychopathology improvement and higher response and completion rates than ziprasidone treatment, while ziprasidone was superior for weight change and lipid profile.

UR - http://www.scopus.com/inward/record.url?scp=26444456116&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=26444456116&partnerID=8YFLogxK

U2 - 10.1176/appi.ajp.162.10.1879

DO - 10.1176/appi.ajp.162.10.1879

M3 - Article

C2 - 16199834

AN - SCOPUS:26444456116

VL - 162

SP - 1879

EP - 1887

JO - American Journal of Psychiatry

JF - American Journal of Psychiatry

SN - 0002-953X

IS - 10

ER -